Menu Search
Equities

EBOS Group Ltd

EBO:NZC

EBOS Group Ltd

Actions
Health CareMedical Equipment and Services
  • Price (NZD)37.50
  • Today's Change0.28 / 0.75%
  • Shares traded121.71k
  • 1 Year change+3.73%
  • Beta0.4341
Data delayed at least 20 minutes, as of Nov 22 2024 04:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year EBOS Group Ltd grew revenues 7.78% from 12.24bn to 13.19bn while net income improved 7.17% from 253.37m to 271.55m.
Gross margin12.38%
Net profit margin2.07%
Operating margin3.61%
Return on assets4.14%
Return on equity11.12%
Return on investment7.22%
More ▼

Cash flow in AUDView more

In 2024, EBOS Group Ltd did not generate a significant amount of cash. However, the company earned 348.24m from its operations for a Cash Flow Margin of 2.64%. In addition the company generated 34.33m cash from financing while 378.12m was spent on investing.
Cash flow per share2.32
Price/Cash flow per share16.29
Book value per share14.04
Tangible book value per share-0.8397
More ▼

Balance sheet in AUDView more

EBOS Group Ltd has a Debt to Total Capital ratio of 40.45%, a lower figure than the previous year's 48.91%.
Current ratio0.9545
Quick ratio0.5671
Total debt/total equity0.6703
Total debt/total capital0.4045
More ▼

Growth rates in AUD

Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
Div yield(5 year avg)3.03%
Div growth rate (5 year)9.59%
Payout ratio (TTM)78.29%
EPS growth(5 years)9.49
EPS (TTM) vs
TTM 1 year ago		6.28
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.